Stories
Blue Plan partnership takes center stage at the SIU Forum
When it comes to finding and preventing FWA, Prime doesn’t work alone. Prime partners closely with Blue Plan clients to be at the forefront of fraud, waste and abuse (FWA) prevention efforts.
November 20, 2019Leaders from Blue Plan clients and Prime’s investigative teams attended this information sharing and networking event. Through presentations, case studies and small-group breakout sessions, forum participants strategized about continued partnership opportunities and how to maximize our unique business model to combat fraud.
Anne Mack, senior director of pharmacy audit and fraud, waste and abuse reflected on the forum as a key driver in high scores from a recent client satisfaction survey where clients shared appreciation of the team’s honesty, transparency, innovation and collaboration.
“We love to meet face to face with the SIU health plan leaders that we deal with daily. They are part of our extended team,” Jo-Ellen Abou Nader, vice president of fraud, waste, and abuse and supply chain optimization, says. “I’ve been in the PBM industry for 20 years and I’ve never seen such great partnership with clients. Clients love how we continue to push forward from an innovation standpoint. We push them to move forward as well.”
Prime’s advanced analytics platform uses integrated medical and pharmacy data
Prime uses a highly effective, two-tiered approach to identify and eliminate fraud, waste and abuse in all forms. Through advanced analytics, powered by SAS – an artificial intelligence vendor that powers data to identify fraud risk – Prime finds bad-acting pharmacies, prescribers and members that add waste and cost to the system.
In its first year deploying the enhanced fraud, waste and abuse (FWA) program, Prime achieved an overall savings for its health plan clients of $279 million. This savings included recovering $51 million recovered through audits and investigations and $228 million of cost avoidance through audits and investigations while focusing on the core areas of retrospective analysis, potential erroneous spending and pharmacy examinations.
Related news
Stories
September 15, 2023
Prime, Magellan Rx Offer Value Plus to Help States Negotiate Value-Based Contracts for CGTs
Reprinted with permission from MMIT By Angela Maas As more and more high-cost…
Stories
September 15, 2023
Prime Therapeutics ranked No. 3 on Minnesota top private companies list
The Minneapolis/St. Paul Business Journal named Prime Therapeutics (Prime) to its annual list,…
Stories
September 5, 2023
Prime Together Foundation: Helping students achieve their dreams
Since 2002, Achieve Twin Cities has equipped more than 85,000 high school students…